In Brief: FDA Approves New Drug to Improve Sexual Desire in Women
The Food and Drug Administration (FDA) has approved a new drug for the treatment of hypoactive sexual desire disorder in premenopausal women. Bremelanotide (to be marketed as Vyleesi) is used on-demand. Bremelanotide is a peptide which acts as a melanocortin receptor agonist. Its mechanism of action is distinct from flibanserin and is thought to have… Read More »